Kimia Farma Tbk PT
IDX:KAEF

Watchlist Manager
Kimia Farma Tbk PT Logo
Kimia Farma Tbk PT
IDX:KAEF
Watchlist
Price: 605 IDR -2.42%
Market Cap: 3.4T IDR

Relative Value

The Relative Value of one KAEF stock under the Base Case scenario is 1 750.54 IDR. Compared to the current market price of 605 IDR, Kimia Farma Tbk PT is Undervalued by 65%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

KAEF Relative Value
Base Case
1 750.54 IDR
Undervaluation 65%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
84
vs Industry
90
Median 3Y
0.5
Median 5Y
0.6
Industry
2.5
vs History
vs Industry
0
Median 3Y
-2.5
Median 5Y
-2
Industry
21.3
vs History
50
vs Industry
50
Median 3Y
5.8
Median 5Y
6.5
Industry
16.7
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-1.7
Industry
24.7
vs History
69
vs Industry
77
Median 3Y
0.7
Median 5Y
0.9
Industry
2.1
vs History
84
vs Industry
77
Median 3Y
1
Median 5Y
1.2
Industry
2.6
vs History
41
vs Industry
57
Median 3Y
3.5
Median 5Y
3.8
Industry
5.1
vs History
vs Industry
27
Median 3Y
13.4
Median 5Y
19.3
Industry
12.8
vs History
vs Industry
31
Median 3Y
13.4
Median 5Y
19.3
Industry
16.3
vs History
50
vs Industry
30
Median 3Y
16
Median 5Y
16.7
Industry
14.9
vs History
12
vs Industry
5
Median 3Y
-12.5
Median 5Y
-12.2
Industry
18.2
vs History
60
vs Industry
73
Median 3Y
0.6
Median 5Y
0.8
Industry
1.9

Multiples Across Competitors

KAEF Competitors Multiples
Kimia Farma Tbk PT Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
ID
Kimia Farma Tbk PT
IDX:KAEF
3.4T IDR 0.3 -1.9 -4.4 -4.4
US
Eli Lilly and Co
NYSE:LLY
725.7B USD 14.8 65.3 35.1 38.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
369.6B USD 4.1 16.9 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7 20.2 14 16
CH
Roche Holding AG
SIX:ROG
212.9B CHF 3.5 25.7 9.6 11.3
CH
Novartis AG
SIX:NOVN
189.4B CHF 4.3 18 10.6 14.2
UK
AstraZeneca PLC
LSE:AZN
165.9B GBP 4.1 29 131.1 197.6
US
Merck & Co Inc
NYSE:MRK
195.3B USD 3.1 11.2 8.4 10.2
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
131.4B USD 2.1 16.7 7.2 10.2
P/E Multiple
Earnings Growth PEG
ID
Kimia Farma Tbk PT
IDX:KAEF
Average P/E: 25.4
Negative Multiple: -1.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
65.3
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.9
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.7
32%
0.8
CH
Novartis AG
SIX:NOVN
18
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
29
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.2
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.7
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ID
Kimia Farma Tbk PT
IDX:KAEF
Average EV/EBITDA: 433.6
Negative Multiple: -4.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.1
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
14
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.6
5%
1.9
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.1
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.4
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ID
Kimia Farma Tbk PT
IDX:KAEF
Average EV/EBIT: 1 867.2
Negative Multiple: -4.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.4
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
16
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.3
6%
1.9
CH
Novartis AG
SIX:NOVN
14.2
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.6
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.2
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1